Twist Bioscience Corporation (TWST)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
133.94 USD
-10.55
(-7.302%) ⇩
(Oct. 16, 2026, 10:35 a.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 10:55 a.m. EDT
Twist Bioscience is a tale of two narratives: a robust revenue recovery and a precarious financial bottom. Over the past six years, the stock has gained nearly 40%, yet the most recent annual performance was a decline, and the company continues to burn cash with negative operating margins. While the 200-day trend line suggests strong momentum, the high valuation relative to sales and the recent insider selling create significant headwinds. The options market mirrors this uncertainty, with heavy positioning at both upside resistance and downside support. For investors, this is a speculative play on future profitability rather than a value opportunity; until the balance sheet turns positive, the high beta and analyst skepticism keep the long-term rating neutral. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.109460 |
| AutoARIMA | 0.122449 |
| MSTL | 0.142193 |
| AutoETS | 0.144897 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 3.70 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.301 |
| Excess Kurtosis | -0.88 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 24.362 |
| Revenue per Share | 7.032 |
| Market Cap | 8,880,379,904 |
| Forward P/E | -178.21 |
| Beta | 2.19 |
| Profit Margins | -31.66% |
| Website | https://www.twistbioscience.com |
As of Oct. 10, 2026, 10:55 a.m. EDT: Speculators are positioning for continued volatility with heavy open interest at key psychological levels. Call buyers are establishing barriers at 200 and 210 strikes, while put buyers are defending the 150 to 170 range. Implied volatility remains elevated across all expirations, suggesting the market expects significant price swings rather than a smooth trend. The mix of volume and open interest indicates a wait-and-see approach pending further earnings clarity.
| Attribute | Value |
|---|---|
| 52 Week Change | 4.1310368 |
| Address1 | 681 Gateway Boulevard |
| All Time High | 219.71 |
| All Time Low | 11.46 |
| Ask | 170.76 |
| Ask Size | 2 |
| Audit Risk | 1 |
| Average Analyst Rating | 1.9 - Buy |
| Average Daily Volume10 Day | 3,748,950 |
| Average Daily Volume3 Month | 2,146,237 |
| Average Volume | 2,146,237 |
| Average Volume10Days | 3,748,950 |
| Beta | 2.192 |
| Bid | 103.32 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 7.112 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 133.94 |
| Current Ratio | 2.672 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 145.05 |
| Day Low | 132.27 |
| Debt To Equity | 24.362 |
| Display Name | Twist Bioscience |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,758,400 |
| Earnings Call Timestamp Start | 1,785,758,400 |
| Earnings Timestamp | 1,785,760,200 |
| Earnings Timestamp End | 1,794,832,200 |
| Earnings Timestamp Start | 1,794,832,200 |
| Ebitda | -115,282,000 |
| Ebitda Margins | -0.26698 |
| Enterprise To Ebitda | -78.09 |
| Enterprise To Revenue | 20.849 |
| Enterprise Value | 9,002,346,496 |
| Eps Current Year | -1.1958 |
| Eps Forward | -0.7516 |
| Eps Trailing Twelve Months | -2.23 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 147.4356 |
| Fifty Day Average Change | -13.49559 |
| Fifty Day Average Change Percent | -0.091535494 |
| Fifty Two Week Change Percent | 413.10367 |
| Fifty Two Week High | 219.71 |
| Fifty Two Week High Change | -85.770004 |
| Fifty Two Week High Change Percent | -0.39037824 |
| Fifty Two Week Low | 23.3 |
| Fifty Two Week Low Change | 110.64 |
| Fifty Two Week Low Change Percent | 4.748498 |
| Fifty Two Week Range | 23.3 - 219.71 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,540,992,600,000 |
| Float Shares | 61,885,330 |
| Forward Eps | -0.7516 |
| Forward P E | -178.2065 |
| Free Cashflow | -64,822,500 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 979 |
| Fullday Change | -10.550003 |
| Fullday Change Percent | -7.3015447 |
| Fullday Price | 133.94 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.51965 |
| Gross Profits | 224,384,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00906 |
| Held Percent Institutions | 1.17171 |
| Implied Shares Outstanding | 66,301,174 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,759,190,400 |
| Long Business Summary | Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California. |
| Long Name | Twist Bioscience Corporation |
| Market | us_market |
| Market Cap | 8,880,379,904 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_242825322 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -136,716,992 |
| Next Fiscal Year End | 1,790,726,400 |
| Non Diluted Market Cap | 10,508,736,079 |
| Number Of Analyst Opinions | 12 |
| Open | 143.88 |
| Operating Cashflow | -53,072,000 |
| Operating Margins | -0.30648002 |
| Overall Risk | 8 |
| Phone | 800 719 0671 |
| Previous Close | 144.49 |
| Price Eps Current Year | -112.008705 |
| Price Hint | 2 |
| Price To Book | 18.832958 |
| Price To Sales Trailing12 Months | 20.566051 |
| Profit Margins | -0.31662 |
| Quick Ratio | 1.98 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.92308 |
| Region | US |
| Regular Market Change | -10.550003 |
| Regular Market Change Percent | -7.3015447 |
| Regular Market Day High | 145.05 |
| Regular Market Day Low | 132.27 |
| Regular Market Day Range | 132.27 - 145.05 |
| Regular Market Open | 143.88 |
| Regular Market Previous Close | 144.49 |
| Regular Market Price | 133.94 |
| Regular Market Time | 1,792,161,307 |
| Regular Market Volume | 559,088 |
| Return On Assets | -0.13086 |
| Return On Equity | -0.29594 |
| Revenue Growth | 0.232 |
| Revenue Per Share | 7.032 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 66,301,174 |
| Shares Percent Shares Out | 0.1594 |
| Shares Short | 10,567,132 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 12,065,357 |
| Short Name | Twist Bioscience Corporation |
| Short Percent Of Float | 0.201 |
| Short Ratio | 4.94 |
| Source Interval | 15 |
| State | CA |
| Symbol | TWST |
| Target High Price | 215.0 |
| Target Low Price | 45.0 |
| Target Mean Price | 163.66667 |
| Target Median Price | 188.5 |
| Total Cash | 166,839,008 |
| Total Cash Per Share | 2.661 |
| Total Debt | 108,590,000 |
| Total Revenue | 431,798,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.23 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 82.75435 |
| Two Hundred Day Average Change | 51.185654 |
| Two Hundred Day Average Change Percent | 0.61852527 |
| Type Disp | Equity |
| Volume | 559,088 |
| Website | https://www.twistbioscience.com |
| Zip | 94,080 |